Viatris Inc. is set to gain a significant commercial boost for its newly-obtained interchangeable biosimilar Semglee (insulin glargine-yfgn), with the product moving to preferred status on pharmacy benefit manager Express Scripts’ largest national formulary from 1 January 2022.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?